Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

Published:2023-05 Issue: Volume:59 Page:101955
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Veerman G.D. Marijn,Boosman Rene J.,Jebbink Merel,Oomen-de Hoop Esther^ORCID,van der Wekken Anthonie J.,Bahce Idris,Hendriks Lizza E.L.^ORCID,Croes Sander,Steendam Christi M.J.,de Jonge Evert,Koolen Stijn L.W.,Steeghs Neeltje,van Schaik Ron H.N.,Smit Egbert F.^ORCID,Dingemans Anne-Marie C.,Huitema Alwin D.R.,Mathijssen Ron H.J.^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer;Peters;Cancer Treat Rev,2016

2. The impact of brain metastases and associated neurocognitive aspects on health utility scores in EGFR mutated and ALK rearranged NSCLC: a real world evidence analysis;O'Kane;Oncologist,2019

3. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?;Hendriks;Lung Cancer,2014

4. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer;Reungwetwattana;J Clin Oncol,2018

5. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib;Heon;Clin Cancer Res,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance;European Journal of Medicinal Chemistry;2024-11

2. Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study;Neuro-Oncology;2024-08-07

3. Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC;JTO Clinical and Research Reports;2024-04

4. Clinical significance of TMEM229A Q200del mutation in lung adenocarcinoma;2023-06-22